UroGen Pharma Ltd.
URGN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$34.49
KIRA · Stoqly’s AI analyst, in plain words
- UroGen Pharma Ltd. had $110M of revenue in fiscal 2025, up 21.4% on the year before. Over five years, revenue changed +56.2% a year on average.
- Its operating margin was −113.7%, down 6.7 pts: of every 100 in sales, about −114 is left after running the business.
- UroGen Pharma Ltd. lost $153M in fiscal 2025.
- Free cash flow was −$163M in fiscal 2025, −148.2% of revenue.
- UroGen Pharma Ltd. has $30.3M more cash than debt.
Market cap
—
P/E
—
Revenue
$110M
Net income
−$153M
Free cash flow
−$163M
Operating margin
−113.7%
UroGen Pharma Ltd. in 30 seconds · fiscal 2025
Are sales growing?
+21.4%
Yes. Sales grew 21.4% last year.
Does it make a profit?
−139.8%
No. It lost money last year.
Does profit turn into cash?
−148.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
What UroGen Pharma Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- UroGen Pharma Ltd.
- CIK
- 0001668243
UroGen Pharma Ltd. · URGN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $48.0M | $64.4M | $82.7M | $90.4M | $110M |
| Revenue growth | 307.2% | 34.0% | 28.5% | 9.3% | 21.4% |
| Gross margin | 89.3% | 88.1% | 88.7% | 90.2% | 88.7% |
| Operating margin | −192.1% | −122.8% | −79.2% | −107.1% | −113.7% |
| Net income | −$111M | −$110M | −$102M | −$127M | −$153M |
| Net margin | −230.7% | −170.6% | −123.6% | −140.4% | −139.8% |
| Diluted EPS | −$4.96 | — | — | — | — |
| Cash | |||||
| Cash from operations | −$84.9M | −$87.6M | −$76.4M | −$96.8M | −$162M |
| Capital expenditure | $0.8M | $0.3M | $0.2M | $0.3M | $0.3M |
| Free cash flow | −$85.6M | −$87.8M | −$76.6M | −$97.1M | −$163M |
| FCF margin | −178.3% | −136.4% | −92.6% | −107.4% | −148.2% |
| Share count change | 2.6% | — | — | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $89.1M | $100.0M | $151M | $283M | $160M |
| Debt incl. finance leases | $0.0M | $97.5M | $98.6M | $124M | $130M |
| Shareholders' equity | $8.4M | −$89.4M | −$65.2M | −$8.8M | −$105M |
| Current ratio | 5.1x | 5.4x | 5.4x | 6.0x | 4.0x |
| Returns and quality | |||||
| Return on equity | −211.6% | — | — | — | — |
| Return on tangible equity | −1,317.2% | — | — | — | — |
| Piotroski F-score | 3 | 4 | 5 | 5 | 1 |
| Altman Z'' | −12.8 | −13.1 | −10.1 | −6.2 | −15.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$4.8M
3 insiders
Of sales under plans
27%
$1.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
UroGen Pharma Ltd. · URGN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $34.49 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001668243). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.